Amicus Therapeutics (FOLD) Misses Q2 EPS by 4c

Amicus Therapeutics (NASDAQ: FOLD) reported Q2 EPS of ($0.15), $0.04 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $94.5 million versus the consensus estimate of $89.83 million.

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• RH (RH) Tops Q2 EPS by $2.31
• KeyBanc Starts Celanese (CE) at Overweight